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in recognition that women with severe anemia account for a disproportionately 
large number of acute medical problems and deaths, this workshop brought 
together interested parties representing some of the best knowledge and expe- 
rience in South Asia to examine the data on anemia and maternal mortality and 
to discuss the development of a mechanism to identify and treat women at high 
risk. In making recommendations for greater efficacy and effectiveness of inter- 
ventions, workshop participants were careful not to compromise or otherwise 
replace the existing focus on treating women with mild or moderate anemia, 
because these women too are at risk (or at least there is insufficient evidence to 
show that they are not at risk), except when there is clear evidence to the contrary. 
The recommendations from this workshop could have far-reaching impli- 
cations within and beyond the South Asian region and have been framed in a 
manner that should be directly useful to policymakers and program planners as 
they strengthen and expand programs, since the information needed by policy- 
makers does not flow automatically from scientific consensus and technological 
feasibility. We need to build bridges between those who have done the science 
and developed the technology, those who deliver the services, and those with the 
power to make the political and financial decisions. Questions of cost, effec- 
tiveness, benefits and risk in relation to gains, and performance of the technol- 
ogy within the environmental, socioeconomic, and cultural context of the target 
population, as well as the identification of the intended beneficiaries, their 
needs, and their social and economic circumstances, all enter into the agenda 
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for policy formulation. This workshop addressed in part the last of these topics: 
the identification of the intended beneficiaries of new programs to prevent and 
treat severe anemia. 
THE PROBLEM 
The latest statement on iron deficiency from the UN ACC/SCN (1997) describes 
the problem of anemia as "a public health emergency fully equivalent to epi- 
demics of infectious diseases." The workshop participants were aware that the 
elimination of anemia could do more than any other single measure to achieve 
the goals of development, because anemia affects not only women of child- 
bearing age, but males and females of all age groups. Furthermore, the huge toll 
that this problem takes in economic terms is becoming increasingly evident. A 
recent Micronutrient Initiative study (Ross and Horton 1998) revealed that in 
South Asia alone, economic losses attributable to iron deficiency amount to 
more than US$5 billion annually, which is i% to 2% of the gross domestic prod- 
uct of many countries in the region. Despite being the most widespread of all 
nutritional deficiencies, iron deficiency is the most neglected, and it constitutes 
a real brake on human development. 
THE CHALLENGE 
All analyses of trends in the prevalence of anemia from the 1970s to the 1990s 
have failed to show any significant improvement, and progress in eliminating 
anemia compares poorly with progress in eliminating iodine deficiency disor- 
der and vitamin A deficiency over the same period (MI and INF igg8). The 
problem is compounded by the fact that iron supplementation during preg- 
nancy, lactation, and early childhood is effective in eliminating iron deficiency 
anemia under controlled and supervised conditions, yet under field conditions 
its effectiveness in most developing countries has been unimpressive (Viteri 
1998). As a result, progress in reducing levels of iron deficiency anemia in 
women and children relative to the modest goal set at the 1990 World Summit 
for Children (a reduction by one-third of 1990 levels) is bound to be disap- 
pointing unless we act now. The challenge is to approach the problem both 
creatively and strategically. 
The question is whether severe anemia can be identified and treated before 
and during pregnancy as a means to reduce maternal mortality. The problem is 
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compounded if conventional wisdom is challenged by asking whether there is 
enough evidence to conclude that maternal anemia is caused predominantly by 
dietary iron deficiency and whether universal iron supplementation is the 
appropriate way to treat all levels of anemia during pregnancy. 
THE POSSIBLE COMPLEMENTARY SOLUTIONS 
The workshop participants recognize the complex causes of the problem and its 
interrelationship with diet and disease. We also know that there is no single 
intervention to be universally advocated. Deciding which of an array of possi- 
bilities to undertake is not an "either—or" situation, but an "and—and" one. 
Supplementation for at-risk groups, fortification, dietary modification, control 
of parasitic diseases, and education of policymakers, professionals, and the 
public all have their places. The relative prerequisites, costs, constraints, and 
opportunities of these approaches must all be explored in any given situation to 
determine the appropriate mix of interventions. 
THE ISSUES 
There are four fundamental issues relating to the efficacy and effectiveness of 
iron supplementation (in some form) in safely improving iron status. Although 
these issues must be considered in the context of pregnancy and maternal out- 
comes, they should also be viewed in a broader context. 
+ Multiple integrated interventions: Integrated interventions could mutually 
reinforce one another. For instance, the focus on supplementation can 
benefit from and be reinforced by greater attention to other approaches, 
such as fortification and dietary diversification. Both supplementation and 
fortification could be used to improve iron status before pregnancy. 
+ Operational effectiveness: In the broader context, technological problems 
are not nearly as serious as operational ones related to making programs 
work in the communities where iron-deficient people live. Issues of supply 
and logistics, the motivation and training of health-care providers, com- 
munications and community participation, and partnership-building across 
a wide spectrum of players (public and private) are all equally important in 
ensuring the effectiveness and sustainability of efforts to eliminate iron 
deficiency and anemia in large populations. Many of these needs interact 
and are mutually reinforcing. 
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+ All age groups at risk: We also need to look at iron deficiency anemia 
throughout the human life cycle arid make consistent recommendations for 
its elimination, given that interventions could have longitudinal and longer- 
term impacts from infancy to childhood to adolescence and pregnancy. For 
instance, to effect a reduction in maternal anemia, iron status must be 
improved well before pregnancy. 
+ Beyond iron: In developing countries, iron is not the only nutrient lacking 
from the diet. Recent evidence that vitamin A, 13-carotene, and zinc can help 
reduce maternal morbidity and mortality gives reason to consider developing 
an approach to combat the whole spectrum of micronutrient deficiencies 
(Jameson 1993; Caulfield etal. 1999; Coutsoudis etal. 1999; Shankar etal. 
1999; West et al. 1999). This approach would further improve the cost- 




The following section presents analyses of the association between anemia and 
maternal mortality (presented during the workshop by David Rush), the impli- 
cations of the accepted definition of anemia (presented by George Beaton), and 
epidemiologic data on the prevalence of anemia and the programs to address this 
problem now in place in India and Bangladesh (presented by Faruk Ahmed, 
Subadra Seshadri, and Kamala Krishnaswami). Discussion of these issues served 
as a preamble to the workshop's core deliberations on the programmatic and 
research implications of severe anemia and maternal mortality. 
MATERNAL MORTALITY AND ANEMIA 
On careful review, the underlying basis for the consensus that all forms of ane- 
mia cause maternal mortality is insecure: there are crucial gaps in the body of 
knowledge supporting current programs for preventing and controlling anemia. 
The three linked assumptions that underlie current thinking about the impact 
of maternal anemia on maternal mortality are stated and analyzed below. 
CRITICAL ANALYSIS OF ASSUMPTION I 
The assumption: Anemia during pregnancy, in contrast to severe anemia, is related causally to 
maternat mortality, and treatment of anemia with iron can, in large part, reverse this risk. 
With the exception of treatment by transfusion in cases of incipient cardiac fail- 
ure (hematocrit < 0.13), there is no documentation that the risk of mortality is 
reduced by treating anemia (Fullerton and Turner 1962). However, there is a 
strong relationship between severe anemia and maternal death. 
5 
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Table i presents the results of all studies of anemia during pregnancy from 
which relative risk of maternal mortality could be calculated. Each study had lim- 
itations. Only the most recent (McDermott et al. 1996) measured hemoglobin 
prospectively. None estimated whether treatment of anemia affected outcome. 
Only two presented data relating mild or moderate anemia to mortality rate, and 
these gave contradictory results. (We assume that the other reports omitted men- 
tion of mild and moderate anemia because these conditions were unrelated to 
increased risk of death.) Nonetheless, the relationship of maternal mortality to 
severe anemia (hemoglobin < 70 or Ba g/L) was remarkably consistent: severe 
anemia was associated with about a fourfold increase in risk of death. 
On the basis of this fragmentary evidence, a reasonable working assumption 
is that the risk of maternal mortality increases steeply with severe anemia. 
Although the available data confirm only an association, not cause and effect, 
the strength of the association makes it appropriate to presume a causal rela- 
tionship while more definitive data are sought. Thus, action to correct severe 
anemia should probably be taken while we struggle to better understand the prob- 
lem. In contrast, the evidence for a relationship between maternal morality and 
moderate anemia is both scanty and contradictory. Therefore, until further data 
are available, moderate levels of anemia are probably best considered unrelated 
to excess maternal mortality, and correcting moderate anemia should be given 
lower priority than preventing and treating severe anemia. Research is urgently 
needed to clari& the relationship between level of prior anemia on one hand and 
maternal survival and pregnancy outcome on the other and to determine the 
extent to which prophylaxis and treatment modil* risk of morbidity and mortality. 
CRITICAL ANALYSIS OF ASSUMPTION 2 
The assumption: It is unnecessary to specify the causes of anemia at an individual or population 
level, because maternal anemia is caused predominantly by dietary iron deficiency, and therefore 
iron supplementation can reverse the risk of maternal death associated with anemia. 
Causes of Anemia 
Anemia in poor women in developing countries has a variety of causes, which 
often occur in combination, especially if the anemia is severe. Thus, in any one 
area there may be a mix of dietary iron deficiency (due to low iron intake or low 
bioavailability, caused by high intake of iron binders such as phytate or tannins), 
folate deficiency, bleeding (vaginal or caused by hookworm or other parasites), 
malaria (particularly in primigravida and young women), hemoglobinopathy 
(e.g., sickle cell disease or thalassemia), and other concurrent infections such as 
HfV infection. 
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Reference Site 
Liewelyn-jones Hospital, 
1965 Kuala Lumpar, 
Malaysia 
for which relative risk could be calculated. 
Nn. of 
Criteria for anemia subjects —- 
Hb c 65 gIL; all 73 048 
sabjects in hospital; 
parenteral iroe given; 
no data on when 
Hb was measared 
Harrison 1979 Hospitat, Level of anemia 
Zaria, Nigeria not specified; 
odds ratio catcslated 
from reported data 
Harrison and Hospital, na 
Rossiter 1985 Zaria, Nigeria 
Hb c 9° giL; 
92% of women who 
died were admitted 
as emergencies, 
37% of momen who 
died were morihsnd 
at time of admission 
na urban: 2.1 
Rural: 5.9 
Hct RR  0.14 1.34 
0.15—0.24 1.05 
0.25—0.29 0.75 
0.30—0.44 1.00  0.45 3.30 
Hospital, Case—control stady; 
Cosakry, Gainea anemia not de8ned 
Diallo et al. 1995 Hospital, Hb < iso g/L; 
Conakry, Guinea reported data 
inconsistent 
Saris 1995 Hospital, Moderate anemia: 
Punjab, India Hb 70—109 gIL; 
sesere anemia: 
Hb .c 7o gIL 
102 deaths; na 
338 controls 
Rural Malawi Prospective study; 3 740 
sesere anemia: 
Hct < 0.25 
13 191 1 408 2.8 










Hb = hemoglobin, na = not available, Hct = hewatocrit. 








Chi et al. 1981 12 teaching 
hospitals, 
Indonesia 
Harrison 1982 Hospital, 
Zaria, Nigeria 















et at. 1992 
2.1 
McDermott 
et at. 1996 
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InterreLationship of Iron with Other Nutrients 
Iron can compete with zinc for intestinal absorption and is affected by ingestion 
of vitamin A. Concurrent tea intake reduces iron absorption because of the 
inhibitory effects of its polyphenolic substances (tannins). 
Response to Community-Based Programs of 
Iron SuppLementation During Pregnancy 
Sloan et al. ('992), Cook and Reddy (1996), and Yip (1996) have commented 
on the discrepancy between evidence from clinical trials, which indicates the 
efficacy of iron supplementation in raising iron stores and hemoglobin levels 
during pregnancy, and the absence of any convincing evidence that community- 
wide or population-based programs of iron supplementation have a notable 
impact on iron stores or any other indices of maternal or perinatal health. 
The findings of the meta-analysis of Sloan et al. ('992) are provocative. 
These researchers summarized data from 24 randomized trials meeting their cri- 
teria of adequate study design and publication between 1966 and 1989. Nine of 
these trials were from developing countries and concentrated on the effects of 
iron supplementation during pregnancy. On average, there was a trivial impact 
(increase in hemoglobin of 2 gIL relative to control) with traditional doses of 
up to 6o mg elemental iron daily. A strikingly similar mean difference between 
daily and weekly iron supplementation for pregnant women (2.47 g/L, 95% 
confidence interval -0.38 to 2.43 g/L) was recently reported by the Micro- 
nutrient Initiative (Beaton and McCabe 1999); the result was based on eight 
clinical trials in developing countries. However, in the review by Sloan et al. 
(1992) there was an appreciably greater impact with higher doses of iron: with 
an iron dose of more than 120 mg daily, the mean increase in hemoglobin was 
i6 gIL greater than for controls (Table 2). 
Another important observation in the meta-analysis of Sloan et al. ('992) 
was the strong relationship between mean initial hemoglobin level and mean 
response to therapy for the studies conducted in developing countries (Table 2). 
When the initial mean hemoglobin level was relatively high (111—120 gIL), iron 
treatment led to only a small increment (5 g/L) in the hemoglobin concentra- 
tion relative to controls. In fact, the effect of supplementation on hemoglobin 
level in studies with high initial mean hemoglobin was half or less than half the 
effect in studies with lower initial mean hemoglobin (Table 2). Another provoca- 
tive finding, one of potentially great programmatic significance, is that for the 
lowest initial mean hemoglobin levels (< 100 g/L), the impact of intervention 
was less (mean increase io g/L more than controls) than for initial mean 
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Table 2. Mets-analysis of 24 randomized trials of 
iron supplementation in pregnancy (1966_1989).* 
Change in Hb level 
relative to control (g/L) 
Mean Range 
Daily dose elemental iron (mg) 
G6o 2 —l7toll 
61—90 10 6 to 15 
91—120 12 6 to 22 
>120 i6 9t016 
Mean initiat Hb level (giL)t 
<100 10 2t017 
100—110 13 —3 to 25 
111—120 5 —12 to 12 
>120 — 
Hb = hemoglobin. 
*Data from Sloan et al. (1992). 
tData for studies from devetoping countries only. 
hemoglobin levels between ioo and no g/L, for which the increase averaged 
13 gIL more than controls. This could be a chance finding, but, in the absence 
of alternative data, it needs to be addressed with utmost seriousness. What we 
know about the physiology of iron absorption would lead us to expect the oppo- 
site trend: at lower hemoglobin levels and presumably worse iron deficiency, 
absorption should increase. One explanation for the anomalous finding may be 
that in populations with lower hemoglobin levels, anemia is less often due to iron 
deficiency alone and therefore may be less responsive to iron therapy. 
Given both physiologic- and measurement-based regression to the mean 
(i.e., with no intervention, those with the lowest measured levels will, upon 
remeasurement, have the greatest real and apparent increases in hemoglobin 
level), it is essential that studies estimating hemoglobin level include untreated 
or differently treated comparable controls. The authors of the trials reviewed by 
Sloan et al. (1992), as well as those who have completed any subsequent trials, 
should be asked to reanalyze their results and to stratify them by initial hemo- 
globin level, or, even better, they should be asked to share their original data, 
which would save valuable time, effort, and resources. A rational policy to 
ameliorate the effects of severe anemia in pregnancy is probably impossible with- 
out this information, and analysis of extant data, rather than the repetition of 
studies to gather the necessary data, could save years of work. 
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The preceding discussion supports the contention that iron supplementa- 
tion must be considered in context. Prior or concurrent attention to the other 
causes of anemia, including infection, seems obligatory. It is a matter of great 
urgency to explore how this can be done, given limited material and human 
resources in the developing world, particularly since the health of women has 
often been a low priority. 
BRIEF ANALYSIS OF ASSUMPTION 3 
The assumption: Clinical screening for anemia is insensitive. 
Although screening for moderate anemia by clinical signs has beenjudged poor, 
the sensitivity of clinical screening for severe anemia has been judged very good 
to excellent (Gjorup et al. 1986). 
Given that the sensitivity of clinical screening is high for detecting severe ane- 
mia but much lower for detecting moderate anemia, the strategies for identify- 
ing severe anemia are likely to differ considerably from those focusing on 
moderate anemia. 
CONCLUSION 
It is reasonably clear that maternal death is strongly associated with severe ane- 
mia, whereas moderate anemia is not likely related to excess maternal mortality. 
This suggests that the prevention and treatment of severe anemia deserve sub- 
stantially higher priority than they have been accorded to date, particularly in 
South Asia. In addressing these needs, concurrent attention to causes of anemia 
beyond iron deficiency is imperative. Fortunately, given the high sensitivity of 
clinical screening for severe anemia, the ability to identify and, in turn, treat 
severely anemic women appears a reasonably manageable task within the South 
Asian context. 
IMPLICATIONS OF THE DEFINITION OF ANEMIA 
David Rush's presentation reflected on the foundation for action on anemia, 
noting that this foundation is incomplete. The accepted reference values for 
hemoglobin during pregnancy also relate to this foundation, having been estab- 
lished according to maximal hemoglobin concentrations rather than on the basis 
of the functional consequences of different hemoglobin concentrations. When 
iron needs during pregnancy are defined on a functional basis, adverse outcomes 
are found to be associated with very high and very low hemoglobin levels, but not 
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with moderate deficiency. The functional cutoff for significant clinical out- 
comes related to low hemoglobin levels appears to be around 70 or 8o gIL. 
The current cutoff values for iron status during pregnancy were determined 
by the World Health Organization, which used reference mean values for women 
of European ancestry obtained from the Centers for Disease Control and 
Prevention. Levels two or more standard deviations below the mean were defined 
as "low." In other words, no functional criteria were considered when the 
reference values were established. 
A functional approach to defining anemia would fundamentally change the 
way we think about iron programs: rather than attempting to bring all women 
to a hypothetical, population-based target hemoglobin level, such programs 
might address the functional needs of the individual. If a functional definition 
is used, the iron programs that we continually lament as unsuccessful may actu- 
ally be effective. Table 3 presents data from three studies of pregnant women who 
received iron and folate supplementation. If the definition of anemia was a 
hemoglobin level of less than no g/L, more than 50% of the women in two of 
the studies remained anemic at the end of the study period. However, if 90 g/L 
represents a hemoglobin level free of adverse functional consequences, these 
programs may in fact have been highly effective in functional terms. In addition 
to the problem of definition of anemia and its impact on programs, no current 
programs focus on the particular problem of severe anemia. 
Finally, to succeed in treating anemia during pregnancy, perhaps it is time 
to abandon our current criteria for the success of an iron program, i.e., achiev- 
ing maximal hemoglobin levels and raising hemoglobin levels above some ulti- 
mately arbitrary level. Instead, we should focus on the "tails" of the hemoglobin 
distribution. We might then he able to address the clinical outcomes associated 
with very low as well as very high hemoglobin levels. 
Table 3. Prevalence of anemia in pregnant women 
receiving iron and fotate supplementation.* 
Settisg; prevalence of anemia (%) - 
Definition of anemia Wevt lava Malami Maloka 
(Nb level, gIL) (n = 139) (n = 216) (p = 399) 
< 110 51.1 56.9 19.5 
< 100 12.2 28.2 6 
<90 0 9.3 1.3 
<70 0 0 0 
Nb = hemoglobin. 
*Reprodaced from Beaton and McCabe (1999). All stadies excloded 
severe anemia at baseline; grospv receiving daily (60 mg) and meekly 
(2 x 6o mg) sspplemests were pooled. 
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PREVALENCE OF SEVERE ANEMIA IN INDIA AND BANGLADESH AND 
CURRENT PROGRAMS TO ADDRESS ANEMIA IN PREGNANCY 
Four main conclusions can be drawn from the presentations during the workshop. 
First, although overall levels of anemia in Bangladesh are very high, estimates 
vary widely. Prevalence data on severe anemia are almost nonexistent, so the sit- 
uation concerning severe anemia is uncertain. Nonetheless, from the scanty 
data that are available, it appears that severe anemia during pregnancy is less fre- 
quent in Bangladesh than in India and may affect 2% to 5% of pregnant women. 
If these prevalence estimates, far lower than those for India and Nepal, prove 
accurate, it will be important to identify and understand the reasons. 
Second, according to the latest national survey by the Institute of Nutrition 
and Food Science, dietary intake 0f iron in Bangladesh is only 58% 0f the 
Indian-derived recommended daily intake. in the past, reported intakes were 
much higher, but the food composition tables used for previous surveys over- 
estimated the iron content of rice. In addition to these low overall intakes, nearly 
all iron consumed is from vegetable sources and thus of low bioavailability. 
Third, a multiple-state survey carried out by the Indian Council of Medical 
Research in 198 5/86 found that 13.1% of pregnant women were severely anemic, 
whereas 33.6% and 40.8% were moderately and mildly anemic, respectively. 
More recent national data do not exist, but the results of several large studies sug- 
gest that these rates have not declined appreciably. 
Finally, treatment of severe anemia in pregnancy, in both India and 
Bangladesh, requires identification of the technical and financial impediments 
to better care of this disorder. Although both countries have policies for iden- 
tifying and referring severely anemic pregnant women through the primary 
health-care system, implementation of these policies is inadequate, and many 
women receive no treatment other than iron prophylaxis, which itself is inade- 
quately implemented. 
PART III 
Proceedings of the 
workshop 
Workshop participants concurred that severe anemia is strongly associated with 
maternal death in South Asia and is barely addressed by current programs. 
Moreover, there are few data to support the effectiveness of current community- 
based iron prophylaxis programs. Perhaps it is time to pay special attention to 
severe anemia. The first step is to develop and test interventions to prevent and 
treat severe anemia through the primary health—care system. 
PROGRAMMATIC RESPONSE FOR PREVENTING SEVERE ANEMIA 
Recognizing the difficulties of treating severe anemia through the primary 
health-care system, one discussion group at the workshop attempted to devise 
schemes for preventing the condition. After presentation of their results, pre- 
vention became a major issue for the duration of the workshop. The scheme 
developed by the working group is presented below. 
I. Targets 
1.1. Pregnant women 
1.2. Adolescent females (io—ig years of age) 
+ unmarried, newly married, pregnant 
+ in school, out of school 
+ formal-sector employment, informal-sector employment, unemployed 
1.3 Newly married, nonpregnant women 
13 
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2. Packages 
2.1 Pregnant women receive: 
s iron tablets 
+ dietary advice 
+ community-specific intervention based on presumed diagnosis 
2.2 Adolescent females receive: 
s iron tablets, drinks, or premixes 
+ action-oriented public health education 
+ dietary advice 
+ community-specific intervention based on presumed diagnosis 
2.3 Newly married, nonpregnant women receive: 
+ weekly iron supplement 
+ counseling on eating iron-rich foods, taking iron tablets, delaying 
pregnancy, and other related topics 
+ other services by preferential access 
2.4 Policymakers and senior managers are targeted to receive information, 
education, and communication (lEG) 
3. Preventive strategy 
3.1 Major interventions 
+ supplementation (pharmacological) 
* diet diversification 
s food fortification 
5 public health measures, especially in relation to malaria, hookworm 
or roundworm, Cwrd,a, other parasites 
3.2 Cross-cutting issues 
+ compliance: supervised administration, education system, health system 
+ captive audiences: schools, other institutions 
+ logistics and supplies 
+ decentralization 
s private sector involvement 
s lEG and "positioning" of severe anemia to change behaviours 
+ policy (especially national) 
+ private sector, nonprofit organizations, nongovernmental organizations 
.s. production and supply of high-quality premixes and drinks 
s marketing of low-cost supplements 
s sharing of costs of lEG 
+ private practitioners 
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+ external monitoring and evaluation of system 
+ training for supply and logistics 
+ financial resources: collaborating agencies, state government, com- 
munities (where they are willing to pay) 
4. Top five things we want to know 
4.1. Does using different approaches for different target groups work? 
What are the outcomes and impacts? 
4.2. What is the role of the private sector in supplying and distributing 
supplements? 
4.3. Will adolescent-to-adolescent counseling work? 
4.4. How can schools, companies, and other institutions be used in iron 
supplementation programs? 
4.5. What is the feasibility of fortification? What are the markets for forti- 
fication? What "vehicles" can be used for fortification? Where would 
fortification be appropriate? 
OPERATIONAL RESEARCH FOR TREATMENT OF SEVERE ANEMIA 
PROPOSED TREATMENT REGIMEN FOR SEVERE ANEMIA 
USING THE PRIMARY HEALTH-CARE SYSTEM 
Treatment of severely anemic pregnant women requires their identification and 
an appropriate response. The logistic and financial constraints associated with 
universal hemoglobin testing rule out laboratory assessment for initial identifi- 
cation, so clinical screening must be the foundation of any community-based 
response. During the workshop, a working group was charged with devising a 
model for treatment at the community level. The model they proposed is pre- 
sented in Fig. i. 
Under this model, all pregnant women would undergo clinical screening for 
severe anemia at no later than 20 weeks' gestation. Those diagnosed as severely 
anemic, if not late in the pregnancy or presenting other complications, would 
receive high-dose oral supplementation with iron and folate, dietary counseling, 
and treatment for other possible causes of severe anemia not related to iron. The 
basis for the additional, non-iron treatment would depend on the woman's 
community and the prevalence there of related factors, such as malaria or 
helminth infection. Women identified as severely anemic who are late in pregnancy 
or who present with complications would receive hospital-based treatment. 
Clinical screen for severe anemia I month after initial screen 
I _____ 
- — Validation of negative result 
F-lb estimation at I 
sentinel sites —, 
Fig. i. Suggested model for treating severe anemia in pregnancy. Hb = hemoglobin. 
Those not diagnosed as severely anemic would receive the standard iron pro- 
phylaxis currently provided in both India and Bangladesh. 
One month after the initial screening, all women not referred to hospital 
would undergo a second clinical screening. For women identified as severely 
anemic during the first screening, the second screening would be a follow-up to 
determine response to treatment; for women not originally identified as severely 
anemic, the second screening would be an additional check on their status later 
in pregnancy. Those in whom there has been a response to treatment, as well as 
those never identified as severely anemic, would receive standard iron prophylaxis 
for the remainder of their pregnancies. Anyone identified as severely anemic at 
the second clinical screening would be referred to hospital. 
Measuring hemoglobin level in all women would be prohibitively expensive 
and logistically trying for the primary health-care systems in Bangladesh and 
India, but it may be important for monitoring the validity of the clinical screen. 
One meeting participant was particularly concerned about the sensitivity of 
Clinical screen for severe anemia 
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by 20 weeks gestation 
positive result — — 
— 
negative result _______________ — Validation of 
I Hb estimation at 
— sentinel sites/ 
Complications or> 36 weeks gesta] 
yes no 
Referral to Basic package for severe anemia 
Thana Health 
Complex .- Iron tablets 
(Bangladesh) + Dietary advice 
or district hospital -0 Community-specific intervention 
(India) based on presumed diagnosis 
positive result 
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clinical screening for monitoring efficacy of treatment and identifying mild or 
moderate cases of anemia. Therefore, it was suggested that sentinel sites be set 
up to validate the clinical estimation of iron status through regular hemoglobin 
measurement. 
RESEARCH MODEL FOR TESTING COMMUNITY-BASED SCHEME 
FOR TREATMENT OF SEVERE ANEMIA 
After group discussion about the proposed treatment model, another working 
group was given the responsibility to devise an operational research study to test 
the model; the study they devised is presented in Fig. 2. A primary objective for 
such research would be to establish whether severe anemia can effectively be 
reversed through activities undertaken in the primary health-care system. 
Before the study, it will be necessary to determine the baseline rate of severe 
anemia at delivery in the study area, preferably a sentinel community where the 
risk of iron deficiency anemia is high. This could be accomplished through a 
"run-in study" of hemoglobin level (or hematocrit) for all women late in preg- 
nancy. During the study itself, all pregnant women in the study area would be 
screened for severe anemia by 20 weeks' gestation and would be assigned to one 
of three treatment regimens: usual treatment (with monitoring) in their primary 
health-care system; an "enhanced" version of their local health—care system, 
with emphasis on training field workers to perform clinical screening for severe 
anemia, a standard additional treatment based on "a presumed diagnosis" related 
to the possible causes of severe anemia in that area (e.g., malaria or helminth 
infection), a guaranteed supply of iron and folate supplements, and follow-up 
screening i month after the initial assessment to evaluate response to treatment 
and to refer to tertiary care if needed; and training of field workers in clinical 
screening for severe anemia followed by referral to hospital-based care for par- 
enteral administration 0f iron. Each woman entering the study would undergo 
a final hemoglobin measurement late in pregnancy (at approximately the same 
stage as for the run-in study [about 36 weeks]). 
This design allows conclusions to be drawn about the reversal of severe ane- 
mia in individuals and about reductions in overall rates of severe anemia at 
delivery (through comparison of the rates of anemia found during the run-in 
study and the main study). 
After intense deliberation, the group suggested that such trials should have 
the following characteristics. 
+ The number of subjects must be large enough to obtain a firm answer to the 
question. The aim might be to lower by at least half the national rate of 





Screening by trained 
Current screening method field workers 
Usual treatment Enhanced usual treatment Parenteral iron 
,- 
Verify clinical screening by close monitoring of Hb Level 
(with appropriate modification of treatment, if necessary) 
,, 
Fig. 2. Research design for testing community-based treatment of severe anemia. Hb = hemoglobin. 
severe anemia (currently 13% in India). The number of participants needed 
is large, especially if design effects are accounted for. 
+ Considering the prohibitive cost and logistic burden 0f laboratory testing 
in a community—based intervention, clinical screening for severe anemia is 
almost certainly necessary and would be sensitive enough if performed in 
Run-in phase 
Determine Hb level 
of all pregnant women 
at 36 weeks gestation 
PRE-STUDY 
IDENTIFICATION OF SEVERE 
ANEMIA DURING PREGNANCY 
INTERVENTION 
Determine Hb level of all participants at 36 weeks gestation 
Outcomes 
Comparison across areas of rates of severe anemia. 
before and after intervention 
Change in Hb levels among severely anemic women 
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standard, optimal ways. Training and supervision to maintain adequate 
sensitivity and specificity must be a priority. 
+ Workshop participants believed that it would not be ethically acceptable to 
give a placebo to women identified as severely anemic. Therefore, a ran- 
domized controlled trial at the individual level is technically impossible. (If 
random assignment at the individual level were done without placebo con- 
trols, there is a high likelihood that "controls" —women diagnosed and told 
of their condition and referred to seek treatment from available community 
resources — would do just that.) 
+ Workshop participants believed that in one arm of the trial women should 
be given parenteral iron (for all women who are willing to accept it). This 
strategy would confer several benefits: parenteral administration of iron 
may be the only treatment that works, and this arm would thus serve as a pos- 
itive control (given that it represents the best result that oral iron could pos- 
sibly achieve, bypassing issues of gastrointestinal absorption and compliance 
with pill—taking regimens). 
+ Subjects in another arm of the trial would received an enhanced version of 
the current treatment. The enhancements would include standardized, 
monitored clinical screening early in pregnancy; validation of diagnosis 
through measurement of hemoglobin level; and deworming and malaria 
prophylaxis in areas of high prevalence. 
+ All subjects would undergo frequent monitoring to determine response to 
treatment, and special attention and treatment modification would be avail- 
able for those with inadequate response. 
+ The control arm of the trial would be the continuation, with monitoring, 
of current pO4icy and activities. 
The trial would be judged in two ways: 
+ In the run-in phase, the rate of severe anemia among all pregnant women 
in the study area would be estimated from hemoglobin or hematocrit meas- 
urements at a set stage in late pregnancy. During the trial, hemoglobin or 
hematocrit would again be measured for all pregnant women at the same 
stage of late gestation. Although hemoglobin or hematocrit measurement 
during the run-in phase may be tedious, it is the only way to feasibly deter- 
mine an area-wide reduction in rates of severe anemia attributable to the 
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intervention, free of the effects of both physiologic- and measurement- 
based regression to the mean. 
+ In the test areas (to be defined by the researchers after the run-in phase), 
actual change in hemoglobin can be measured and adjusted (as well as pos- 
sible) for the natural changes in hemoglobin concentration associated with 
pregnancy. 
It would also be advisable to determine whether intensive iron treatment is 
associated with any dangers, such as effects on zinc absorption, on rates ofpreg- 
nancy-induced hypertension, on rates of infection in mother and infant, on 






Maternal mortality is one of the most urgent public health problems in the 
developing world. Rates in industrialized countries are as iow as 3 or 4 per 
100 000 births. Among women in many developing countries, rates are at least 
100- to 200-fold higher. In the worst affected areas and taking multiple preg- 
nancies into account, as many as io% of all women may die in childbirth. 
Although both the causes (complications of induced abortion, toxemia of preg- 
nancy, obstructed labor, and obstetric hemorrhage and infection) and the ways 
to prevent most cases of maternal mortality are well understood, the role of 
nutrition, and particularly the role of nutritional anemia, is not. 
SEVERE ANEMIA IN PREGNANCY 
In the developing world, severe anemia during pregnancy is associated with very 
high relative risk of maternal death, perhaps two- to six-fold, and severe ane- 
mia is especially common in South Asia. National surveys in India have reported 
a rate of severe anemia of 13% during pregnancy; if the relative risk of death is 
four times as high among severely anemic women as among women without 
severe anemia, this proportion accounts for 37.4% of maternal deaths (there is 
little or no evidence that moderate or mild anemia is associated with maternal 
mortality). Thus, three-quarters of all maternal deaths are potentially prevent- 
able by eliminating severe anemia. 
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ROLE OF PREVENTION AND REVERSAL OF SEVERE ANEMIA 
It is therefore urgent that we determine whether preventing or reversing severe 
anemia during pregnancy reduces rates of maternal mortality (and morbidity). 
Unfortunately, there have been few or no demonstrations that severe anemia in 
pregnancy can he prevented or reversed, and these goals must be achieved before 
effects on mortality can be tested. 
Given the practical difficulties in identifying and treating severe anemia in 
pregnancy through the primary health-care system, intervention to prevent this 
condition by maximizing iron stores among nonpregnant women is an attractive 
option. It may be necessary to combine continuous maintenance 0f supple- 
mental iron with intensive, relatively short-term supplementation. 
Intervention before marriage, to help unmarried girls and women achieve 
adequate iron stores, may reduce rates of severe anemia in pregnancy; this strat- 
egy should be tested. 
Focused interventions to improve iron stores during the interval between 
marriage and the onset of the first pregnancy and for periods between preg- 
nancies may reduce rates of severe anemia in pregnancy, and these strategies 
should also be tested. Furthermore, this approach may be more efficient than 
iron supplementation long before marriage. 
The treatment of severe anemia, although one of the stated objectives of pri- 
mary health care during pregnancy, has in reality been neglected. It is of the 
highest priority and deserves far greater attention, especially in South Asia, 
where rates 0f severe anemia are among the highest in the world. Women in 
whom severe anemia is diagnosed are likely to be highly motivated to seek and 
comply with treatment. 
PROMOTING DEMAND AS AN ADJUNCT STRATEGY 
Given the potentially high recurring costs of long-term prevention, it is impor- 
tant to test the ability to create demand for supplementation, as well as food 
fortification. This option could serve as an adjunct to supplementation by 
governments and private agencies, particularly for women who are mildly or 




APPLY CURRENT KNOWLEDGE AND POLICIES 
The public, health workers, and policymakers must be educated about the enor- 
mity of the problem of maternal mortality and its very strong associations with 
severe anemia during pregnancy. Every effort should be made to adhere with 
current policies to address severe anemia during pregnancy. 
DEVELOP METHODS TO PREVENT AND REVERSE SEVERE ANEMIA 
Although the association between severe anemia and maternal mortality is 
strong, a causal relationship has not been established. A strategy to give univer- 
sal and immediate attention to preventing and treating severe anemia would 
inevitably deflect attention from current programs of universal iron and folate 
supplementation. Even though these programs are not explicitly limited to the 
treatment of mild and moderate anemia, they are unlikely to have much, if any, 
effect on severe anemia. Given the paucity of relevant data, it appears prudent 
not to promote or initiate worldwide changes in anemia control programs with- 
out first demonstrating in pilot projects that it is possible to prevent or reverse 
severe anemia and that such change confers benefit (i.e., results in lower maternal 
mortality rates). So far, such prevention or reversal has not been demonstrated 
even in intensive, small-scale trials. Reversal of the condition does not imply 
achieving hemoglobin levels defined as "normal," but rather levels around 
23 
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90 gIL. It has also not been demonstrated that reversal of the condition confers 
health benefits, specifically by reducing maternal or infant morbidity or mor- 
tality rates. 
FOCUS ON PREVENTION 
The concept of prevention is appealing. Perhaps the adverse effects of severe ane- 
mia can be optimally reversed only by making changes before pregnancy occurs. 
It is also preferable that high doses of a potentially toxic substance — in this case, 
iron — be avoided during a vulnerable period such as pregnancy. 
Although the prevention of anemia in early childhood is attractive in its own 
right, workshop participants felt that increasing iron stores in the period just 
before marriage and childbearing might prevent severe anemia in subsequent 
pregnancy. (It remains to be demonstrated that programs before marriage can 
indeed prevent later anemia. It will therefore be helpful, even before trials are 
started, to have more reliable data on the natural history of anemia and iron 
stores — in particular, whether and to what extent iron status earlier in life 
predicts later risk of anemia and the modifications to these relationships that may 
be caused by duration and intensity of menstrual flow, diet, disease, and para- 
site burden.) 
The workshop participants concluded that trials of iron supplementation 
and other interventions to build iron stores and reverse anemia before marriage 
should receive high priority in an overall strategy aimed at preventing severe 
anemia in pregnancy. 
Strategies to recruit newly married girls and women into multifaceted pro- 
grams to prevent later anemia should be developed and tested. Registration for 
marriage, where it exists, is a possible sampling frame to identifr such women. 
Furthermore, since newly married women are very likely to become pregnant 
shortly, reversal of their anemia will often exert an immediate influence on the 
course of the pregnancy. 
Preventive efforts during the periods between pregnancies could be important. 
This strategy is attractive because it could be integrated with family planning pro- 
grams among women who could be screened and involved in treatment as part 
of such activities. 
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CONDUCT TRIALS ON REVERSAL 
Although prevention of anemia is probably desirable, there are currently mil- 
lions of South Asian women entering and continuing pregnancy who are already 
severely anemic. Therefore, it is urgent to attempt to reverse severe anemia 
during pregnancy through large-scale, field-based programs. We believe that 
large—scale trials attempting reversal should be initiated as soon as possible, using 
the method presented in Part III ("Research Model for Testing Community- 
Based Scheme for Treatment of Severe Anemia"). 
DETERMINE IMPACT OF PREVENTION ON 
MATERNAL MORTALITY AND MORBIDITY 
Many of the workshop participants are convinced that, if it becomes clear that 
severe anemia can be prevented or reversed, the trial or trials should be extended 
in duration and numbers of subjects to determine the impact of prevention or 
reversal on maternal mortality and morbidity and other perinatal outcomes. 
Inevitably, there will be controversy about the need for such a demonstra- 
tion; many will assert that the value of reversing severe anemia is self-evident and 
does not require a further demonstration of outcome effects. 
There are several arguments for conducting such further studies: 
+ There will be costs associated with prevention or reversal programs. It will 
be easier to justify new resources or the modification of current anemia con- 
trol programs if the utility for the well-being of the mother and child has 
been clearly demonstrated and quantitatively estimated. 
+ Iron is not wholly benign it can be toxic, and the justification for its use 
demands an estimation of the ratio between risk and benefit. 
+ For any new intervention other than iron, it would be taken for granted that 
effectiveness and danger would have to be estimated before promotion of 
worldwide extension of programs. Many (but not all) of the workshop par- 
ticipants believe that this standard should hold for iron as well. 
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